Better U
- NAD IV Therapy
- Vitamin IV Therapy
- Ketamine Therapy
- Chelation Therapy
- Peptide Therapy
West Hollywood, CA
Peptide Therapy clinics in West Hollywood
West Hollywood has an entertainment industry and LGBTQ-focused aesthetic and hormone medicine market, and peptide therapy has grown into a visible slice of the local wellness market. The clinics we track across the Sunset Strip, Melrose, and the Design District range from physician-led longevity practices to medspa-adjacent wellness offices offering sermorelin blends and growth hormone peptides. Most local prescribers have training or admitting privileges within the Cedars-Sinai and UCLA Health network. The scene here skews toward clinics integrating peptides with HRT, aesthetics, and gender-affirming care. The regulatory landscape shifted sharply in 2023 and 2024 when the FDA placed several widely prescribed peptides on its Category 2 bulk substances list, restricting which ingredients compounding pharmacies could legally source. That changed access overnight for BPC-157, CJC-1295, ipamorelin, and thymosin beta-4. Sermorelin and tesamorelin remain FDA-approved for specific indications, and reputable West Hollywood clinics now draw a clearer line between approved peptides and off-label research compounds than they did two years ago.
Citrin Longevity
- IV Therapy
- Hyperbaric Oxygen Therapy (HBOT)
- Peptide Therapy
- Red Light Therapy
- Erectile Dysfunction (ED) Treatment
Wellness Center for Healing Los Angeles
- Vitamin IV Therapy
- PRP Therapy
- Ozone Therapy
- IV Therapy
- Arthritis Treatment
Freedom Laser
- Ozone Therapy
- Laser Therapy (LLLT)
- Hyperbaric Oxygen Therapy (HBOT)
- Ketamine Therapy
- Red Light Therapy
Regenerative Medicine LA
- Vitamin IV Therapy
- Ozone Therapy
- Multiple Sclerosis (MS) Treatment
- Arthritis Treatment
- Peptide Therapy
Remedy Place
- NAD IV Therapy
- Vitamin IV Therapy
- IV Therapy
- Hyperbaric Oxygen Therapy (HBOT)
- Cryotherapy
Regulatory context
A note on California's peptide therapy rules.
Most research peptides used in regenerative medicine (BPC-157, TB-500, CJC-1295, ipamorelin) are not FDA-approved drugs. Sermorelin and tesamorelin hold FDA approvals for specific indications. In 2023 and 2024 the FDA placed several peptides into Category 2 on its Bulk Drug Substances Nominated for Use in Compounding list, which restricts 503A compounding pharmacies from sourcing those ingredients for patient-specific prescriptions. Section 503A covers traditional pharmacies; Section 503B covers FDA-registered outsourcing facilities operating under cGMP.
-
California Business and Professions Code Division 2 Chapter 9 (Pharmacy Law)
Governs compounding, licensure, and sourcing under the California State Board of Pharmacy. -
California Code of Regulations Title 16 Section 1735 et seq.
Sets compounding standards for sterile and non-sterile preparations. -
California Business and Professions Code Section 2052
Defines practice of medicine and limits who may prescribe or administer drugs. -
California Naturopathic Doctors Act
Grants licensed NDs limited prescriptive authority under formulary advisory committee rules.
The California State Board of Pharmacy inspects sterile compounding facilities under stringent state rules that often exceed USP 797. The Board has issued citations for sourcing non-compliant bulk ingredients and for office-use stocking that should have flowed through a 503B. Non-resident pharmacies shipping into California must hold a current non-resident permit; the Board publishes disciplinary actions and annual inspection findings. Clinics dispensing from in-office stock of compounded peptides are examined closely.